Weekly reeval Mar 15 (HELD). MSFT at .55, significantly below MA50 () and MA200 (). ATH was . Down 22% from ATH. Azure AI thesis intact — Google Cloud 48% growth YoY validates cloud/AI demand. 66% capex surge raising investor concerns. fPE 21x modest relative to growth. Analyst target (50% upside!). Iran war has potential negative impact on MSFT government contracts but minimal. Technical picture concerning. Conviction stays 7 — thesis intact, but not adding to position at this point. Watching for Azure re-acceleration in next earnings Apr-May.
Weekly re-eval Mar 8. Held at $408.96 vs entry $405.13. Only held position with positive P&L (+0.9%). Azure +39-40% reaccelerating, RPO +110% to $625B — massive enterprise AI cloud moat. 47% operating margin expanding. At 21x forward vs historical 28x = still discounted. Iran war/macro not a direct threat to enterprise cloud spend. Raise from 7 to 8 — thesis increasingly validated. Target $530, stop $375.
Downgrading 7→6. New concern: WSJ reports MSFT's pivotal AI product is running into big problems. Combined with cloud growth slowing (quarterly report already caused selloff) and now Feb jobs miss (-92K) adding recession risk, the premium AI thesis faces dual threats. Azure +39% is good but if Copilot/enterprise AI isn't monetizing, the growth story has a hole. Stagflation scenario (rising inflation + rising unemployment) is particularly bad for MSFT's enterprise spending thesis — IT budgets get cut in recessions. Stock at $409 vs $555 July peak. Need to investigate AI product issue before deciding whether to trim. Hold for now but conviction drops.
MSFT thesis neutral. No fresh negative news this week. Cloud/Office revenue is sticky. Iran/rate headwind applies (same 4.12% yield pressure on premium valuations). 'SaaS-pocalypse' from AI disruption is a slow-burn risk for MSFT's enterprise software business. Wayve investment (.2B with NVDA) shows continued AI ecosystem bets. Conviction maintained at 7 — hold but no urgency to add here.
Fair Value Distribution — percentile bands
19.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
15.0%/yr
±3.5% · revenue growth to justify current price
FCF-Based Reverse DCF
21.8%/yr
±3.2% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Azure reaccelerating at +39% with RPO at $625B — the backlog alone is larger than most tech companies' revenue. Copilot monetization just starting across Office 365's 400M+ seat base. OpenAI partnership gives MSFT the most defensible AI distribution moat in enterprise software.
Down 17% in 3 months from war-deleveraging — macro headwinds are real and MSFT trades as a risk asset now. $80B+ annual capex on AI infrastructure needs to generate returns; if Copilot uptake disappoints, the capex looks like overinvestment. Antitrust risk from EU and DOJ on cloud bundling.
Azure growth below 30%, Copilot churn above 20%, antitrust forced unbundling
Updated Mar 11
MSFT confirmed -22% YTD with HR restructuring news adding pressure. Q2 FY2026: revenue .3B (+17%), Azure +39%, but CapEx surged 66% to .5B/quarter with B projected for full FY2026. Market questioning ...
MSFT down 20% YTD, worst Mag-7 performer. Market pricing in risk that AI software makes MSFT enterprise suite obsolete. Azure +39% growth is real but sentiment overwhelmingly negative. April 29 earnin...
Azure +39-40% confirms AI demand. Commercial RPO +110% to 625B signals enterprise AI cloud scale commitments. 47% operating margin with 17-18% revenue growth. CapEx surge (49.3B H1) compressed FCF but...
Azure reaccelerated to 39%, commercial RPO surged 110% to $625B, and operating margin expanded to 47%. GAAP EPS was massively inflated by a $10B OpenAI dilution gain. Adjusted EPS +24%. CapEx intensit...